Memory Support System training in mild cognitive impairment: Predictors of learning and adherence.
Liselotte De Wit, Melanie Chandler, Priscilla Amofa and 6 others
PMID 31538854WHAT IT FOUND
Patients with mild cognitive impairment who learned the Memory Support System better at the end of a 10-day program were more likely to keep using it at 6, 12, and 18 months.
Baseline global cognition predicted how well they learned the system.
Key findings
01Higher baseline global cognition (DRS-2 score) significantly predicted better learning of the Memory Support System at the end of training.
02Better MSS learning phase at the end of training was a significant predictor of adherence to the system at 6, 12, and 18 months post-training.
03Depression and memory-related self-efficacy did not significantly predict learning or adherence to the MSS system.
STILL TO COME
How it was doneWhat they foundWhat it means for OTsWhat it means for SLPs
Read the rest of this summary
You get three full summaries a month, free, and we do not ask for a card. Search, the TL;DRs and your library stay unlimited either way.
What it does not show
The study population was predominantly non-Hispanic whites, limiting generalizability to minority populations. Participants received MSS as part of a multicomponent intervention program (including physical exercise, computerized brain fitness, education, and support groups), so it is unclear if the findings apply when MSS is used as a standalone intervention. The analysis was a secondary examination of a randomized trial, focusing only on those who received MSS training, which may introduce selection bias regarding the specific characteristics of this subgroup.
Declared interests
No conflict of interest was reported by the authors.
The easy way to misread this
Do not assume that depression or low self-efficacy will prevent a patient from learning or adhering to a memory support system, as these factors were not significant predictors in this study. Additionally, because participants received MSS as part of a larger multicomponent program, these results may not fully apply to patients receiving MSS as a standalone therapy.